TransMedics Group (NASDAQ: TMDX) reported Q4 EPS of $0.12, $0.19 better than the analyst estimate of ($0.07). Revenue for the quarter came in at $81.2 million versus the consensus estimate of $68.49 million.

GUIDANCE:

TransMedics Group sees FY2024 revenue of $360-370 million, versus the consensus of $330.2 million.

For earnings history and earnings-related data on TransMedics Group (TMDX) click here.